ReviewFrontiers in pharmacology2025
Therapeutic potential of common Phytoestrogens found in traditional Chinese medicine in chronic kidney diseases.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, phytoestrogens in traditional Chinese medicine (TCM)-a class of estrolike active components naturally occurring in medicinal plants-have gradually emerged as a research hotspot in the treatment of various diseases due to their multi-target regulatory potential. These metabolites are abundant in TCM, and an increasing body of evidence indicates that they have beneficial effects in chronic kidney diseases. Research demonstrates that phytoestrogens can alleviate renal pathological damage by regulating the expression of pro-inflammatory cytokines, reducing oxidative stress, and inhibiting the activation of fibrosis pathways. The application of phytoestrogens as a therapeutic strategy for chronic kidney diseases is highly promising. This review comprehensively summarizes the status of TCM phytoestrogens in chronic kidney disease research and elaborates in detail on various types of these compounds, such as baicalin and puerarin, as well as their protective effects on chronic kidney disease observed in animal and cell experiments. Additionally, we highlight the advantages of TCM phytoestrogens in the regulation of chronic kidney disease and discuss their potential clinical significance and future research directions in this field. These findings will provide a promising avenue for the development of drugs aimed at treating chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.